Rituximab on Adult-onset frequenTly rElApsing or steroid dependent nephrotic syndrome study

Rituximab on Adult-onset frequenTly rElApsing or steroid dependent nephrotic syndrome study - A-TEAM study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041475

Enrollment

Registered

2020-10-01

Start date

2020-09-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adult-onset frequently relapsing or steroid dependent nephrotic syndrome

Interventions

IDEC-C2B8 control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with frequent relapsing type or steroid-dependent nephrotic syndrome in the past, and remission (urine protein <0.3 g / gCr) was confirmed by urine protein quantification more than twice after the start of steroid treatment for the latest recurrence

Exclusion criteria

Exclusion criteria: 1. Patients with secondary nephrotic syndrome (including suspicion) 2. Patients who have been treated with rituximab 3.Patients with eGFR of 44mL / min / 1.73m2 or less 4.Patients with an infectious disease

Design outcomes

Primary

Measure	Time frame
Cumulative recurrence-free rate at 48 weeks from the start of study drug administration	—

Countries

Japan

Contacts

Public ContactYOSHITAKA ISAKA

Osaka University Graduate School of Medicine Division of Nephrology

isaka@kid.med.osaka-u.ac.jp0668793857

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026